Baxalta

Activities: Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Finance

Shareholders approve Shire's merger with Baxalta

Will create 'the leading global biotechnology company in rare diseases and other highly specialised conditions', the firms say
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Latest EU drug approvals span range of health issues

Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Finance

Shire to buy Baxalta for US$32bn

Creating a global leader in rare diseases
Research & Development

Baxalta agrees $1.6bn cancer deal with Symphogen

Will advance novel therapeutics against six targets
Research & Development

Baxalta opens Global Innovation Centre in Cambridge, MA, US

Will serve as the firm's HQ for R&D, oncology, biosimilars and business development
Finance

Shire makes hostile all-stock US$30bn bid for Baxalta

To create the leading global biotechnology company focused on rare diseases
Research & Development

Baxalta appoints Jacopo Leonardi as EVP and President Immunology

Biopharmaceutical firm specialises in developing and manufacturing plasma-based therapies for rare diseases
Subscribe now